Clinical Trials

Status
Published

Recently Activated

SHOW MORE
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S1400K

A PHASE II STUDY OF ABBV-399 (PROCESS II) IN PATIENTS WITH C-MET POSITIVE STAGE IV OR RECURRENT SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)

Status Notes
Effective on 2/5/18 at 2:00 pm PST, S1400K will be activated.

This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
Research Committee(s)
Lung Cancer
Activated
02-05-2018
Open
Accrual
0%
SWOG Clinical Trial Number
S1619

A Feasibility Trial of Neoadjuvant Cisplatin - Pemetrexed - Atezolizumab with Adjuvant Maintenance Atezolizumab in Resectable Malignant Pleural Mesothelioma

Status Notes
This study is open to accrual effective November 3, 2017 at 2:00 p.m. Eastern.
Research Committee(s)
Lung Cancer
Activated
11-03-2017
ClinicalTrials.gov Registry Number
NCT03228537
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S1613

A Randomized Phase II Study of Pertuzumab and Trastuzumab (TP) compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification

Status Notes
Effective 10/09/2017 at 2pm Eastern, S1613 will be active for accrual.
Research Committee(s)
Gastrointestinal Cancer
Activated
10-09-2017
Open
Phase
II
Accrual
8%
SWOG Clinical Trial Number
S1400F

A PHASE II STUDY OF MEDI4736 AND TREMELIMUMAB AS THERAPY FOR CHECKPOINT INHIBITOR REFRACTORY SQUAMOUS PATIENTS

Status Notes
Effective immediately on 11/3/17, S1400F will be re-opened for patient accrual.

This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study.
Research Committee(s)
Lung Cancer
Activated
10-02-2017
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S1607

A Phase II Study Of Combining Talimogene laherparepvec (T-VEC) And PD-1 Blockade With Pembrolizumab In Patients With Advanced Melanoma Who Have Progressed On Anti-PD1 Therapy

Status Notes
Effective 10/02/2017 at 2pm Eastern, S1607 will be active for accrual.
Research Committee(s)
Melanoma
Activated
10-02-2017
ClinicalTrials.gov Registry Number
NCT02965716